Literature DB >> 2546590

On the relationship between leukotriene and lipoxin production by human neutrophils: evidence for differential metabolism of 15-HETE and 5-HETE.

C N Serhan1.   

Abstract

Lipoxygenase (LO) products generated by human PMN were examined utilizing a gradient-HPLC and rapid spectral detector which permitted continuous UV-spectral monitoring of leukotrienes, lipoxins and related oxygenated products of arachidonic acid. When exposed to the ionophore A23187, PMN generated LTB4 and its omega-oxidation products as well as LXA4, LXB4, and 7-cis-11-trans-LXA4 from endogenous sources. Addition of 15-HETE changed the profile of products generated by activated PMN and led to a time- and dose-dependent increase in lipoxins and related compounds while the production of LTB4 and its omega-oxidation products was inhibited. Results of time-course and radiolabel studies revealed that 15-HETE is rapidly transformed within 15 s to 5,15-DHETE and conjugated tetraene-containing products, and that the inhibition of leukotriene formation followed a similar time-course. In contrast, PMN did not generate either lipoxins or related products from 5-[3H]HETE, nor did 5-HETE block leukotriene formation. Stimulated PMN generated 5,15-DHETE from exogenous 5-HETE, while in the absence of ionophore, 5-HETE was transformed to 5,20-HETE. These results indicate that PMN can generate lipoxins and related products from endogenous sources and that 15-HETE and 5-HETE are transformed by different routes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546590     DOI: 10.1016/0005-2760(89)90264-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  Lipoxins and other arachidonate derived mediators in bronchial asthma.

Authors:  C Chavis; I Vachier; P Godard; J Bousquet; P Chanez
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Lipid mediator informatics-lipidomics: novel pathways in mapping resolution.

Authors:  Charles N Serhan; Song Hong; Yan Lu
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

Review 3.  Anti-inflammatory and proresolving lipid mediators.

Authors:  Charles N Serhan; Stephanie Yacoubian; Rong Yang
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

4.  Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids.

Authors:  M E Brezinski; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation.

Authors:  J Clària; M H Lee; C N Serhan
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

Review 6.  Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.

Authors:  Ting Fu; Muthukumar Mohan; Eoin P Brennan; Owen L Woodman; Catherine Godson; Phillip Kantharidis; Rebecca H Ritchie; Cheng Xue Qin
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-17

Review 7.  Lipoxins: eicosanoids carrying intra- and intercellular messages.

Authors:  C N Serhan
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

Review 8.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

9.  Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis.

Authors:  E Thomas; J L Leroux; F Blotman; C Chavis
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

10.  Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway.

Authors:  L Iversen; K Fogh; K Kragballe
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.